DIABETES MELLITUS TREATMENT: A RAPID REVIEW ON INNOVATIVE THERAPIES
DOI:
https://doi.org/10.22159/ajpcr.2019.v12i1.28285Keywords:
Diabetes mellitus, Hypoglycemic agents, Insulin secretagogues, Insulin sensitizers, Patents, Stem cell therapyAbstract
Diabetes mellitus is a chronic and metabolic disorder which results from defects in a section of insulin, action of insulin, or both. Primarily drugs are used to control the symptoms and save life. Secondary aims are to prevent long-term diabetic complications and by eliminating various risk factors to increase longevity. In type I diabetes mellitus, new innovative therapies such as pancreatic transplantation, pancreatic islet transplantation, stem cell therapy, transdifferentiation, and gene therapy are discussed, and regarding type II diabetes mellitus, treatment is based on drugs which stimulates the secretion of insulin such as conventional therapy, antihypoglycemic agents such as insulin, insulin secretagogues, and insulin sensitizers, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, and a list of patents for the treatment of diabetes mellitus are discussed in this review article.
Downloads
References
El-Kaissi S, Sherbeeni S. Pharmacological management of Type 2 diabetes mellitus: An update. Curr Diabetes Rev 2011;7:392-5.
The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415 27.
Vijayan M, Jose R, Jose S, Abraham S, Joy J. Study on quality of life assessment in diabetic retinopathy among patients with type 2 diabetic patients. Asian J Pharm Clin Res 2017;10:116-119.
Muhas C, Naseef P. A review article-gestational diabetes mellitus. Int J Curr Pharm Res 2017;9:1-5.
Furth ME, Atala A. Stem cell sources to treat diabetes. J Cell Biochem 2009;106:507-11.
Couri CE, Voltarelli JC. Autologous stem cell transplantation forearly Type 1 diabetes mellitus. Autoimmunity 2008;41:666-72.
Gross CR, Limwattananon C, Matthees BJ. Quality of life after pancreas transplantation: A review. Clin Transplant 1998;12:351-61.
Demartines N, Schiesser M, Clavien PA. An evidence-based analysis of simultaneous pancreas-kidney and pancreas transplantation alone. Am J Transplant 2005;5:2688-97.
Burke GW 3rd, Vendrame F, Virdi SK, Ciancio G, Chen L, Ruiz P, et al. Lessons from pancreas transplantation in Type 1 diabetes: Recurrence of islet autoimmunity. Curr Diab Rep 2015;15:121-2.
Kerr HR, Hatipoglu B, Krishnamurthi V. Pancreas transplant for diabetes mellitus. Cleve Clin J Med 2015;82:738-44.
Ziaja J, Bozek-Pajak D, Kowalik A, Krol R, Cierpka L. Impact of pancreas transplantation on the quality of life of diabetic renal transplant recipients. Transplant Proc 2009;41:3156-8.
Decker E, Coimbra C, Weekers L. A retrospective monocenter review of simultaneous pancreas-kidney transplantation. Transplant Proc 2009;41:3389-92.
Becker LE, Hallscheidt P, Schaefer SM, Klein K, Grenacher L, Waldherr R. A single-center experience on the value of pancreas graft biopsies and HLA antibody monitoring after simultaneous pancreas kidney transplantation. Transplant Proc 2015;47:2504-12.
Redfield RR, Scalea JR, Odorico JS. Simultaneous pancreas and kidney transplantation: Current trends and future directions. Curr Opin Organ Transplant 2015;20:94-102.
McCullough KP, Keith DS, Meyer KH, Stock PG, Brayman KL, Leichtman AB. Kidney and pancreas transplantation in the United States, 1998-2007: Access for patients with diabetes and end-stage renal disease. Am J Transplant 2009;9:894-6.
Sampaio MS, Poommipanit N, Cho YW, Shah T, Bunnapradist S. Transplantation with pancreas after living donor kidney vs. living donor kidney alone in Type 1 diabetes mellitus recipients. Clin Transplant 2010;24:812-20.
Schenker P, Vonend O, Krüger B, Klein T, Michalski S, Wunsch A, et al. Long-term results of pancreas transplantation in patients older than 50 years. Transpl Int 2011;24:136-42.
Drachenberg CB, Odorico J, Demetris AJ, Arend L, Bajema IM, Bruijn JA, et al. Banff schema for grading pancreas allograft rejection: Working proposal by a multi-disciplinary international consensus panel. Am J Transplant 2008;8:1237-49.
Mora M, Ricart MJ, Casamitjana R, Astudillo E, López I, Jiménez A, et al. Pancreas and kidney transplantation: Long-term endocrine function. Clin Transplant 2010;24:236-40.
Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman A, Magee JC, Cibrik D, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001;71:82-90.
Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States and non-US cases as reported to the United network for organ sharing and the international pancreas transplant registry. Clin Transplant 2005;19:433-55.
Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov 2014;13:278 89.
Ikeda Y, Kudva YC. Human fetal pancreatic islet-like structures as source material to treat Type 1 diabetes. Stem Cell Res Ther 2013;4:159 60.
Aguayo-Mazzucato C, Bonner-Weir S. Stem cell therapy for Type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:139-48.
Bose B, Shenoy SP, Konda S, Wangikar P. Human embryonic stem cell differentiation into insulin secreting β-cells for diabetes. Cell Biol Int 2012;36:1013-20.
Raikwar SP, Zavazava N. Differentiation and lineage commitment of murine embryonic stem cells into insulin producing cells. Methods Mol Biol 2013;1029:93-8.
Tuch B, Hughes T, Evans M. Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes. Diabetes Metab Res Rev 2011;27:928-32.
Ber I, Shternhall K, Ohanuna Z, Goldberg I. Functional, persistent, and extended liver to pancreas trans differentiation. J Biol Chem 2003;278:31950-7.
Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A. Cancer risk associated with use of metformin and sulfonylurea in Type 2 diabetes: A meta-analysis. Oncologist 2012;17:813-22.
Lu J, Herrera PL, Carreira C, Bonnavion R. Alpha cell-specific men1ablation triggers the trans differentiation of glucagon expressing cells and insulinoma development. Gastroenterology 2010;138:1954 65.
Rao MS, Dwivedi RS, Subbarao V, Usman MI, Scarpelli DG, Nemali MR, et al. Almost total conversion of pancreas to liver in the adult rat: A reliable model to study trans differentiation. Biochem BioBiophys Res Commun 1988;156:131-6.
Shen CN, Slack JM, Tosh D. Molecular basis of trans differentiation of pancreas to liver. Nat Cell Biol 2000;2:879-87.
Lardon J, De Breuck S, Rooman I, Van Lommel L, Kruhoffer M, Orntoft T, et al. Plasticity in the adult rat pancreas: Trans differentiation of exocrine to hepatocytelike cells in primary culture. Hepatology 2004;39:1499-507.
Lardon J, Huyens N, Rooman I, Bouwens L. Exocrine cell trans differentiation in dexamethasone-treated rat pancreas. Virchows Arch 2004;444:61-5.
Crasto W, Jarvis J, Khunti K. New insulins and new insulin regimens: A review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J 2009;85:257-67.
Henry RR, Gumbiner B, Ditzler T. Intensive conventional insulin therapy for Type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993;16:21-31.
Si Y, Zhao Y, Hao H, Liu J, Guo Y. Infusion of mesenchymal stem cells ameliorates hyperglycemia in Type 2 diabetic rats: Identification of a novel role in improving insulin sensitivity. Diabetes 2012;61:1616-162.
Xiang AH, Peters RK, Kjos SL. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517-22.
Uwaifo GI, Ratner RE. Differential effects of oral hypoglycaemic agents on glucose control and cardiovascular risk. Am J Cardiol 2007;99:51B-67.
Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009;52:17-30.
Hasslacher C. Safety and efficacy of repaglinide in Type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-91.
Blicklé JF. Meglitinide analogues: A review of clinical data focused on recent trials. Diabetes Metab 2006;32:113-20.
Ceriello A. The post-prandial state and cardiovascular disease: Relevance to diabetes mellitus. Diabetes Metab Res Rev 2000;16:125 32.
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
Ye JM, Dzamko N, Cleasby ME. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: Comparison with metformin. Diabetologia 2004;47:1306-13.
Dabhi AS, Bhatt NR, Shah MJ. Voglibose: An alpha glucosidase inhibitor. J Clin Diagn Res 2013;7:3023-27.
Bruin JE, Erener S, Vela J, Hu X, Johnson JD, Kurata HT, et al. Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells. Stem Cell Res 2014;12:194 8.
Zhou J, Su P, Li D, Tsang S, Duan E. High-efficiency induction of neural conversion in human ESCs and human induced pluripotent stem cells with a single chemical inhibitor of transforming growth factor beta superfamily receptors. Stem Cells 2010; 28:1741-50.
Heffernan C, Sumer H, Verma PJ. Generation of clinically relevantm induced pluripotent stem†(iPS) cells. J Stem Cells 2011;6:109-27.
Gitt AK, Bramlage P, Binz C, Krekler M, Deeg E. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective Dia regis registry. Int J Clin Pract 2001;67:1005-14.
Ahren B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care 2007;30:1344-50.
Lambeir AM, Durinx C, Scharpé S. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.
Barnett A. DPP-4 inhibitors and their potential role in the management of Type 2 diabetes. Int J Clin Pract 2006;60:1454-70.
Pawlak R. Vegetarian diets in the prevention and management of diabetes and its complications. Diabetes Spectr 2017;30:82-8.
Abdelsaid M, Williams R, Hardigan T, Ergul A. Linagliptin attenuates diabetes induced cerebral pathological neovascularisation in a blood glucose independent manner: Potential role of ET-1. Life Sci 2016;159:83-9.
Neumillar J. Review of linagliptin for the treatment of Type 2 diabetes mellitus. Clin Ther 2012;34:993-1005.
Sena CM, Bento CF, Pereira P. Diabetes mellitus: New challenges and innovative therapies. EMPA J 2010;1:138-63.
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Med J 2012;27:269-73.
Chaudhury A, Duvoor C, Dendi VS, Krleti S, Chadaa A, Ravilla R, et al. Clinical review of antidiabetic drugs: Implications for Type 2 diabetes mellitus management. Front Endocrinol 2017;8:1-12.
Abdulazeez SS. Diabetes treatment: A rapid review of the current and future scope of stem cell research. Saudi Pharm J 2015;23:333-40.
Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus-a devastating metabolic disorder. Asian J Biomed Pharm 2014;4:1-7.
Adapa D, Sarangi TK. A review on diabetes mellitus: Complications, management and treatment modalities. Research and reviews. J Med Health Sci 2015;4:1-17.
Baynest HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab 2015;6:1-9.
Penalver JJ, Timon IM, Collantes CS, Gomez FJ. Update on the treatment of Type 2 diabetes mellitus. World J Diabetes 2016;7:354-95.
Khan SE, Cooper ME, Prato SD. Pathophysiology and treatment of Type 2 diabetes: Perspectives on the past, present and future. Lancet 2014;383:1068-83.
Liebl A, Khunti K, Beltran DO, Yale JF. Health economic evaluation of Type 2 diabetes mellitus: A clinical practical focused review. Clin Med Insights J Endocrinol Diabetes 2015;8:13-9.
Mukhopadhyay P, Maity S, Mandal S, Chakraborti AS, Prajapati AK, Kundu PP. Preparation, characterization and in vivo evaluation of pH sensitive, safe Quercetin succinylated Chitosan alginate core shell corona nanoparticles for diabetes treatment. Carbohydr Polym 2017;182:42-51.
Nathan DM. Adjunctive treatment for Type I diabetes. N Engl J Med 2017;377:2390-91.
Ulla A, Khan A, Khan I. Diabetes mellitus and oxidative stress-a concise review. Saudi Pharm J 2016;24:547-53.
Baliga V, Sapsford R. Diabetes mellitus and heart failure-an overview of epidemiology and management. Diab Vasc Dis Res 2009;6:164-71.
Harikumar K, Kumar BK, Hemalatha GJ, Kumar MB, Lado SF. A review on diabetes mellitus. Int J Novel Trends Pharm Sci 2015;5:201-17.
Deshmuk CD, Jain A. Diabetes mellitus: A review. Int J Pure Appl Biosci 2015;3:224-30.
Clarke C. Oral therapy in Type 2 diabetes: Pharmacological properties and clinical use of currently available agents. Diabetes Spectrum 1998;11:211-21.
Kharroubi AT, Darwish HM. Diabetes mellitus: The epidermic of the century. World J Diabetes 2015;6:850-67.
Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A. Metabolic response to sodium-glucose co transporter 2 inhibition in Type 2 diabetic patients. J Clin Invest 2014;124:499-8.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
